Entero’s 5% operating margin trails sector median by 7.74 points
Management expects FY27 MedTech revenue to cross Rs 1,000 cr, while other income contributed only Rs 3.01 cr to pre-tax profit.
Filed 07 Aug 2026, 17:57 IST · after market close · Entero Healthcare Solutions Ltd (ENTERO)
Key takeaways
- Entero reported a 5.00% consolidated operating margin, 7.74 percentage points below the median for 116 reporting Consumer Discretionary peers.
- Management said FY27 MedTech revenue is expected to cross Rs 1,000 cr and expressed high confidence in delivering its FY27 guidance.
- The company said it served more than 72,000 pharmacies and 2,300 hospitals in Q1FY27.
Price around the results
Entero sits near the lower end of its reporting peer set
Entero’s consolidated operating margin was 5.00%, 7.74 percentage points below the 12.74% median among 116 Consumer Discretionary peers that have reported. It ranked 14th from the bottom of that group. Other income was only Rs 3.01 cr, so pre-tax profit was not materially supported by non-operating income.
MedTech is management’s main FY27 growth marker
Management said it expects FY27 MedTech revenue to cross Rs 1,000 cr and expressed high confidence in delivering its guidance for the rest of FY27. The company also said its acquisition strategy is focused on market-consolidation opportunities, including a pan-India approach to acquiring and integrating smaller distributors. Management said large and national distributors could account for 20–30% of the market by FY28 and that Entero expects to benefit from this consolidation.
Q1 distribution reach covered 72,000 pharmacies
The company said it distributed products to more than 72,000 pharmacies and 2,300 hospitals during Q1FY27. These figures provide the operating scale behind management’s consolidation and distribution strategy.
The filing came after market close
Entero filed the consolidated results at 17:57 IST after market close on 7 August 2026. The stock’s immediate response and its comparison with reactions to earlier results are therefore not part of this release.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹1,940 cr |
| Other income | ₹3 cr |
| Expenses | ₹1,844 cr |
| Operating profit | ₹97 cr |
| Operating margin (%) | 5.00% |
| Interest | ₹21 cr |
| Depreciation | ₹12 cr |
| Profit before tax | ₹67 cr |
| Tax | ₹15 cr |
| Net profit | ₹52 cr |
| EPS (₹) | ₹8.77 |
Operating margin of 5.00% compares with a Consumer Discretionary sector median of 12.74% across 116 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Entero distributed products to more than 72,000 pharmacies in Q1FY27.
- Entero distributed products to more than 2,300 hospitals in Q1FY27.
Guidance & outlook
- Management expressed high confidence in delivering its guidance for the rest of FY27.
- Entero expects FY27 MedTech revenue to exceed Rs. 1,000 crore.
- Entero expects large and national distributors’ share to rise to 20–30% by FY28 and expects to benefit from this consolidation.
Expansion
- Entero’s acquisition strategy is to pursue market consolidation opportunities.
- Entero plans a pan-India approach to acquiring and integrating smaller distributors.
What to watch
- Whether consolidated operating margin holds above 5.00%.
- Progress toward management’s FY27 MedTech revenue guidance of more than Rs 1,000 cr.
- Whether distribution reach remains above 72,000 pharmacies and 2,300 hospitals.